×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
FULC – fulcrum therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
FULC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/2
08:41 am
fulc
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 [Yahoo! Finance]
High
Report
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 [Yahoo! Finance]
12/2
08:30 am
fulc
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
High
Report
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
11/24
09:04 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $14.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $14.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Low
Report
Fulcrum Therapeutics (NASDAQ:FULC) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/24
07:19 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/7
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/3
04:45 pm
fulc
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
Medium
Report
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
10/30
11:02 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at Royal Bank Of Canada from $5.00 to $7.00. They now have a "sector perform" rating on the stock.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at Royal Bank Of Canada from $5.00 to $7.00. They now have a "sector perform" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
10/29/2025
07:00 am
fulc
fulcrum therapeutics, inc.
MISS
Report
-5.6%
fulcrum therapeutics, inc.
7/29/2025
06:48 am
fulc
fulcrum therapeutics, inc.
BEAT
Report
-0.3%
fulcrum therapeutics, inc.
5/1/2025
07:00 am
fulc
fulcrum therapeutics, inc.
BEAT
Report
89.6%
fulcrum therapeutics, inc.
2/25/2025
07:00 am
fulc
fulcrum therapeutics, inc.
MISS
Report
0.0%
fulcrum therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/21
04:15 pm
fulc
Form 4 Fulcrum Therapeutics, For: Nov 19 Filed by: Gould Robert J
Medium
Report
Form 4 Fulcrum Therapeutics, For: Nov 19 Filed by: Gould Robert J
11/19
04:21 pm
fulc
Form 144 Fulcrum Therapeutics, Filed by: Gould Robert J
Low
Report
Form 144 Fulcrum Therapeutics, Filed by: Gould Robert J
11/13
09:04 am
fulc
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: Adage Capital Management, L.P.
Medium
Report
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: Adage Capital Management, L.P.
10/29
07:11 am
fulc
Form 10-Q Fulcrum Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Fulcrum Therapeutics, For: Sep 30
10/29
07:05 am
fulc
Form 8-K Fulcrum Therapeutics, For: Oct 29
Medium
Report
Form 8-K Fulcrum Therapeutics, For: Oct 29
10/17
06:41 pm
fulc
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: BlackRock, Inc.
Low
Report
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/19
Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
25.0%
2/14 Form SC 13G Fulcrum Therapeutics, Filed by: GLAXOSMITHKLINE PLC 21.7%
8/19 Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD 21.2%
12/17 Hedge Funds Have Never Been This Bullish On Fulcrum Therapeutics, Inc. (FULC) [Yahoo! Finance News] 15.4%
10/30 Fulcrum Therapeutics (NASDAQ: FULC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 15.1%
2/26 Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD) 13.2%
2/20 Fulcrum Therapeutics to Participate in Upcoming Investor Conferences 10.3%
8/26 Form 8-K Fulcrum Therapeutics, For: Aug 26 8.8%
4/29 Form DEF 14A Fulcrum Therapeutics, For: Jun 11 8.6%
4/16 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 6.6%
2/14 Form SC 13G Fulcrum Therapeutics, Filed by: GLAXOSMITHKLINE PLC 21.7%
8/19 Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD 21.2%
12/17 Hedge Funds Have Never Been This Bullish On Fulcrum Therapeutics, Inc. (FULC) [Yahoo! Finance News] 15.4%
10/30 Fulcrum Therapeutics (NASDAQ: FULC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 15.1%
2/26 Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD) 13.2%
2/20 Fulcrum Therapeutics to Participate in Upcoming Investor Conferences 10.3%
8/26 Form 8-K Fulcrum Therapeutics, For: Aug 26 8.8%
4/29 Form DEF 14A Fulcrum Therapeutics, For: Jun 11 8.6%
4/16 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 6.6%
TOP News Decliners
8/1
Fulcrum Therapeutics to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference
-12.9%
8/14 Form SEC STAFF LETTER Fulcrum Therapeutics, -10.3%
3/10 Fulcrum Therapeutics, Inc. (FULC) Q4 2019 Earnings Call Transcript [The Motley Fool] -9.2%
8/15 Fulcrum Therapeutics (NASDAQ: FULC) had its "outperform" rating re-affirmed by analysts at Svb Leerink Llc. -8.8%
1/21 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.6%
7/17 Form 3 Fulcrum Therapeutics, For: Jul 17 Filed by: Third Rock Ventures GP IV, L.P. -6.9%
4/13 Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease -6.3%
7/18 Form 4 Fulcrum Therapeutics, For: Jul 18 Filed by: Cadavid Diego -6.3%
4/17 Fulcrum Therapeutics (NASDAQ: FULC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.1%
3/5 Form 10-K Fulcrum Therapeutics, For: Dec 31 -4.9%
8/14 Form SEC STAFF LETTER Fulcrum Therapeutics, -10.3%
3/10 Fulcrum Therapeutics, Inc. (FULC) Q4 2019 Earnings Call Transcript [The Motley Fool] -9.2%
8/15 Fulcrum Therapeutics (NASDAQ: FULC) had its "outperform" rating re-affirmed by analysts at Svb Leerink Llc. -8.8%
1/21 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.6%
7/17 Form 3 Fulcrum Therapeutics, For: Jul 17 Filed by: Third Rock Ventures GP IV, L.P. -6.9%
4/13 Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease -6.3%
7/18 Form 4 Fulcrum Therapeutics, For: Jul 18 Filed by: Cadavid Diego -6.3%
4/17 Fulcrum Therapeutics (NASDAQ: FULC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.1%
3/5 Form 10-K Fulcrum Therapeutics, For: Dec 31 -4.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: